142 related articles for article (PubMed ID: 23072371)
1. Bendamustine can severely impair T-cell immunity against cytomegalovirus.
Hosoda T; Yokoyama A; Yoneda M; Yamamoto R; Ohashi K; Kagoo T; Ueno H; Boku S; Yano T
Leuk Lymphoma; 2013 Jun; 54(6):1327-8. PubMed ID: 23072371
[No Abstract] [Full Text] [Related]
2. Cytomegalovirus reactivation with bendamustine in patients with low-grade B-cell lymphoma.
Hasegawa T; Aisa Y; Shimazaki K; Nakazato T
Ann Hematol; 2015 Mar; 94(3):515-7. PubMed ID: 25107463
[No Abstract] [Full Text] [Related]
3. [Development of cytomegalovirus antigenemia in 3 patients with B cell lymphoma treated with bendamustine monotherapy].
Mitsumori T; Sueki Y; Kawashima I; Yamamoto T; Nozaki Y; Nakajima K; Kirito K
Rinsho Ketsueki; 2014 Feb; 55(2):239-43. PubMed ID: 24598192
[TBL] [Abstract][Full Text] [Related]
4. Cytomegalovirus retinitis in relapsed or refractory low-grade B cell lymphoma patients treated with bendamustine.
Yamasaki S; Kohno K; Kadowaki M; Takase K; Iwasaki H
Ann Hematol; 2017 Jul; 96(7):1215-1217. PubMed ID: 28447162
[No Abstract] [Full Text] [Related]
5. [Mechanisms of action and clinical effectiveness of the newly approved anti-cancer drug bendamustine].
Furukawa Y; Hiraoka N; Wada T; Kikuchi J; Kano Y
Nihon Yakurigaku Zasshi; 2011 Jul; 138(1):26-32. PubMed ID: 21747206
[No Abstract] [Full Text] [Related]
6. Bendamustine.
Keating MJ; Bach C; Yasothan U; Kirkpatrick P
Nat Rev Drug Discov; 2008 Jun; 7(6):473-4. PubMed ID: 18511926
[No Abstract] [Full Text] [Related]
7. Cytomegalovirus antigenemia and end-organ disease in Japanese patients treated with bendamustine.
Chiba A; Nakamura F; Nakazaki K; Kurokawa M
Leuk Lymphoma; 2018 Mar; 59(3):749-751. PubMed ID: 28697686
[No Abstract] [Full Text] [Related]
8. A 60-year-old woman with lymphoma and postchemotherapy thickening of the urinary bladder wall. Cytomegalovirus cystitis associated with immunosuppression.
Ali A; Chetty R; Evans AJ
Arch Pathol Lab Med; 2006 Feb; 130(2):217-8. PubMed ID: 16454567
[No Abstract] [Full Text] [Related]
9. A retrospective study evaluating the efficacy and safety of bendamustine in the treatment of mantle cell lymphoma.
Warsch S; Hosein PJ; Maeda LS; Alizadeh AA; Lossos IS
Leuk Lymphoma; 2012 Jul; 53(7):1299-1305. PubMed ID: 22185662
[TBL] [Abstract][Full Text] [Related]
10. Severe CMV reactivation and gastritis during treatment of follicular lymphoma with bendamustine.
Lim SH; Pathapati S; Langevin J; Hoot A
Ann Hematol; 2012 Apr; 91(4):643-4. PubMed ID: 21811782
[No Abstract] [Full Text] [Related]
11. Stevens-Johnson syndrome after treatment with bendamustine.
Lambertini M; Del Mastro L; Gardin G; Levaggi A; Bighin C; Giraudi S; Pronzato P
Leuk Res; 2012 Jul; 36(7):e153-4. PubMed ID: 22480970
[No Abstract] [Full Text] [Related]
12. Clinical experience of bendamustine in relapsed or refractory Hodgkin lymphoma: a retrospective analysis of the French compassionate use program in 28 patients.
Ghesquières H; Stamatoullas A; Casasnovas O; Morschhauser F; Gyan E; Gabarre J; Malphettes M; Clément L; Ferlay C; Brice P
Leuk Lymphoma; 2013 Nov; 54(11):2399-404. PubMed ID: 23410099
[TBL] [Abstract][Full Text] [Related]
13. [Recommendation for the optimal use of bendamustine in Japan].
Ohmachi K; Maruyama D; Nisikori M; Suzuki T; Izutsu K
Rinsho Ketsueki; 2014 Mar; 55(3):311-20. PubMed ID: 24681934
[No Abstract] [Full Text] [Related]
14. Bendamustine produces durable responses with an acceptable safety profile in patients with rituximab-refractory indolent non-Hodgkin lymphoma.
Cheson BD; Friedberg JW; Kahl BS; Van der Jagt RH; Tremmel L
Clin Lymphoma Myeloma Leuk; 2010 Dec; 10(6):452-7. PubMed ID: 21189660
[TBL] [Abstract][Full Text] [Related]
15. Short communication: bendamustine-related hemolytic anemia in chronic lymphocytic leukemia.
Goldschmidt N; Gural A; Ben-Yehuda D; Gatt ME
Cancer Chemother Pharmacol; 2013 Sep; 72(3):709-13. PubMed ID: 23907444
[TBL] [Abstract][Full Text] [Related]
16. Bendamustine-induced "flagellate dermatitis".
Mahmoud BH; Eide MJ
Dermatol Online J; 2012 Nov; 18(11):12. PubMed ID: 23217953
[TBL] [Abstract][Full Text] [Related]
17. Bendamustine: a bridge to longer term solutions in heavily treated Hodgkin lymphoma.
Moskowitz A
Leuk Lymphoma; 2013 Nov; 54(11):2339-40. PubMed ID: 24093891
[No Abstract] [Full Text] [Related]
18. The safety of bendamustine in patients with chronic lymphocytic leukemia or non-Hodgkin lymphoma and concomitant renal impairment: a retrospective electronic medical record database analysis.
Nordstrom BL; Knopf KB; Teltsch DY; Engle R; Beygi H; Sterchele JA
Leuk Lymphoma; 2014 Jun; 55(6):1266-73. PubMed ID: 23987821
[TBL] [Abstract][Full Text] [Related]
19. Bendamustine in CLL: How quickly will today's consensus become tomorrow's memory?
Cheson BD
Leuk Res; 2014 Nov; 38(11):1267-8. PubMed ID: 25260826
[No Abstract] [Full Text] [Related]
20. Phase I-II study of bendamustine in patients with acute leukemia and high risk myelodysplastic syndrome.
Chacar C; Jabbour E; Ravandi F; Borthakur G; Kadia T; Estrov Z; Rios MB; Cortes J; Kantarjian H
Clin Lymphoma Myeloma Leuk; 2012 Jun; 12(3):197-200. PubMed ID: 22578814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
